Skip to main content
DARE logo

Daré Bioscience, Inc. (DARE)

DARENASDAQHealthcareBiotechnology

$0.41Today:+$0.00 (+0.44%)1Y −73.10%

As of Nov 20, 2026 close

Market cap
$6.73M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.41$3.78
Volume (live)
-
Avg. volume (3M)
172.89K

Daré Bioscience (DARE) Key Statistics & Financial Metrics

Daré Bioscience has a $6.73M market cap and a −804.4% TTM net margin as of the Nov 20, 2026 close. Valuation, profitability, balance sheet, dividend and growth figures below.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Stock Price

Current price, 52-week range, and moving averages

Current Price$0.41
1-Day Change+0.44%
52-Week High$3.78
52-Week Low$0.41
YTD Change−76.82%
1-Year Change−73.10%
50-Day MA$0.70
200-Day MA$1.48
Avg Volume (30 day)172.89K

Analyst Price Targets & Consensus

Wall Street analyst ratings and 12-month price targets (90 days)

Analyst ConsensusHold
Analyst Count1

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Growth Rates (YoY)

Year-over-year growth metrics

Revenue Growth+4366.48%

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Source: Market prices and company fundamentals from financial filings. Data as of Nov 20, 2026. Data sources and methodology

Frequently Asked Questions About Daré Bioscience Statistics

Is DARE stock overvalued?

As of the Nov 20, 2026 close, Daré Bioscience (DARE) trades at 4.9x TTM sales.

How much debt does DARE have?

As of its most recent quarterly balance sheet, Daré Bioscience (DARE) has $7.23M of total debt and $12.62M in cash and securities, a net cash position of $5.38M. The current ratio is 0.99 and the quick ratio is 0.99.

How profitable is DARE?

Over the trailing twelve months Daré Bioscience (DARE) lost $10.99M on revenue of $1.37M, with a gross margin of −107.2%, an operating margin of −813.4%, a net margin of −804.4% and a free cash flow margin of −860.6%. On the same TTM basis, return on invested capital is −0.5% and return on assets is −49.1%.

How fast is DARE growing?

Comparing the trailing twelve months with the twelve months before, Daré Bioscience (DARE)'s revenue grew 4366.5%.

Compare these multiples with other companies in the Healthcare sector.